PTK2 and liver cancer: The mode of action of salinomycin as a CSC inhibitor involves various mechanisms, such as attenuating liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signaling pathway [31].